PubMed · 1989 · 55 citations · 19 references
MedicineCell BiologyOncologyBreast OncologyMolecular OncologyMonoclonal AntibodiesImmuno-oncology BiomarkersImmunohistochemistryBone Marrow - Derived CellsBone Marrow AssessmentCancer Cell Line ModelsIndirect Fluorescent Antibody AssayIndirect Immunofluorescence AssayMicrometastatic Disease DetectionMonoclonal Antibodies In CancerMonoclonal Antibodies In Oncology
We have previously shown that occult micrometastases can be detected in the bone marrow of breast cancer patients using a panel of epithelial specific monoclonal antibodies in an indirect immunofluorescent assay. The sensitivity of this assay has been examined using cells from an established human breast cancer cell line (MCF-7) mixed with normal bone marrow at various dilutions from 400 cancer cells/10(6) marrow cells (400:10(6] to 10:10(6). MCF-7 cells were detected at the lowest concentration studied, namely 10:10(6). The number of fluorescent labeled MCF-7 cells counted at each concentration was related to the concentration by a simple nonlinear statistical model. At the concentration of 10:10(6), the model shows that this technique has the sensitivity to detect between two and four MCF-7 cells 95% of the time. Moreover, by extrapolation, the model predicts that even at the very low concentration of 2:10(6), there is a 95% chance of detecting one cancer cell. Therefore, this assay may be a very sensitive method for detecting cancer cells in the bone marrow in vivo.
19